Literature DB >> 33704735

Assessment of Cell-Free microRNA by NGS Whole-Transcriptome Analysis in Cutaneous Melanoma Patients' Blood.

Kevin D Tran1, Rebecca Gross2, Negin Rahimzadeh2, Shanthy Chenathukattil2, Dave S B Hoon1,2, Matias A Bustos3.   

Abstract

MicroRNAs (miRs) are small RNA molecules (18-22 nucleotides) that regulate the transcriptome at a post-transcriptional level by affecting the expression of specific genes. This regulatory mechanism is critical to maintain cell homeostasis and specific functions. Aberrant expression of miRs have been associated with pathobiological processes including cancer. There are few technologies available that are able to profile whole-genome miR expression using minimal amounts of blood samples and without the need for time-consuming extraction steps. Here, we describe the HTG EdgeSeq miR Whole-Transcriptome Assay (WTA) in serum and plasma samples. To identify specific cell-free miR (cfmiR) patterns we have first focused on the analysis of normal donor samples and have then compared these to patients with cutaneous melanoma. The identification of specific cfmiR for melanoma patients will allow for better patient surveillance during targeted and/or checkpoint inhibitor immunotherapy (CII) treatment.

Entities:  

Keywords:  Metastatic melanoma; Plasma; Serum; miR Whole Transcriptome Assay; miRNA

Mesh:

Substances:

Year:  2021        PMID: 33704735     DOI: 10.1007/978-1-0716-1205-7_34

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients.

Authors:  Nathaniel H Fleming; Judy Zhong; Inês Pires da Silva; Eleazar Vega-Saenz de Miera; Bobbi Brady; Sung Won Han; Doug Hanniford; Jinhua Wang; Richard L Shapiro; Eva Hernando; Iman Osman
Journal:  Cancer       Date:  2014-08-25       Impact factor: 6.860

Review 2.  Immunotherapy of Melanoma: Facts and Hopes.

Authors:  Sarah A Weiss; Jedd D Wolchok; Mario Sznol
Journal:  Clin Cancer Res       Date:  2019-03-28       Impact factor: 12.531

3.  High-throughput miRNA profiling of human melanoma blood samples.

Authors:  Petra Leidinger; Andreas Keller; Anne Borries; Jörg Reichrath; Knuth Rass; Sven U Jager; Hans-Peter Lenhof; Eckart Meese
Journal:  BMC Cancer       Date:  2010-06-07       Impact factor: 4.430

Review 4.  Current and future perspectives of liquid biopsies in genomics-driven oncology.

Authors:  Ellen Heitzer; Imran S Haque; Charles E S Roberts; Michael R Speicher
Journal:  Nat Rev Genet       Date:  2019-02       Impact factor: 53.242

5.  MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.

Authors:  Matias A Bustos; Shigeshi Ono; Diego M Marzese; Takashi Oyama; Yuuki Iida; Garrett Cheung; Nellie Nelson; Sandy C Hsu; Qiang Yu; Dave S B Hoon
Journal:  J Invest Dermatol       Date:  2017-05-16       Impact factor: 8.551

6.  Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma.

Authors:  Yuuki Iida; Aaron Ciechanover; Diego M Marzese; Keisuke Hata; Matias Bustos; Shigeshi Ono; Jinhua Wang; Matthew P Salomon; Kevin Tran; Stella Lam; Sandy Hsu; Nellie Nelson; Yelena Kravtsova-Ivantsiv; Gordon B Mills; Michael A Davies; Dave S B Hoon
Journal:  Clin Cancer Res       Date:  2017-04-07       Impact factor: 12.531

7.  Development and validation of a plasma-based melanoma biomarker suitable for clinical use.

Authors:  Ryan Van Laar; Mitchel Lincoln; Barton Van Laar
Journal:  Br J Cancer       Date:  2018-01-23       Impact factor: 7.640

  7 in total
  1 in total

1.  Urine Cell-Free MicroRNAs in Localized Prostate Cancer Patients.

Authors:  Yoko Koh; Matias A Bustos; Jamie Moon; Rebecca Gross; Romela Irene Ramos; Suyeon Ryu; Jane Choe; Selena Y Lin; Warren M Allen; David L Krasne; Timothy G Wilson; Dave S B Hoon
Journal:  Cancers (Basel)       Date:  2022-05-12       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.